Determination of Her-2/Neu Status in Breast Carcinoma: Comparative Analysis of Immunohistochemistry and Fluorescent In Situ Hybridization
- 1 January 2000
- journal article
- research article
- Published by Elsevier BV in Laboratory Investigation
- Vol. 13 (1), 37-45
- https://doi.org/10.1038/modpathol.3880007
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Prognostic significance of HER-2/neu gene amplification status by fluorescence in Situ hybridization of prostate carcinomaCancer, 1997
- FISH detection of HER-2/neu oncogene amplification in early onset breast cancerBreast Cancer Research and Treatment, 1996
- Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.Journal of Clinical Oncology, 1996
- Fluorescence in Situ Hybridization for Detecting ErbB-2 Amplification in Breast Tumor Fine Needle Aspiration BiopsiesActa Cytologica, 1996
- Detection of chromosome aneuploidy in breast lesions with fluorescence in situ hybridization: Comparison of whole nuclei to thin tissue sections and correlation with flow cytometric DNA analysisCytometry, 1995
- Heterogeneity of chromosome 17 and erbB‐2 gene copy number in primary and metastatic bladder cancerCytometry, 1995
- The neu-protein and breast cancerVirchows Archiv, 1995
- Significance of c-erb5-2 amplification and DNA aneuploidy. Analysis in 78 patients with node-negative breast cancerCancer, 1992
- Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.Journal of Clinical Oncology, 1992
- Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancerInternational Journal of Cancer, 1991